Docteur Marie-Caroline GUZIAN

Bibliographie

• Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study

  2017

  ArticlePLoS ONE

• Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics

  2015

  ArticlePLoS ONE

• Can we improve the diagnosis of spondyloarthritis in patients with uncertain diagnosis? The EchoSpA prospective multicenter French cohort

  2012

  ArticleJoint Bone Spine

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CH D'AVIGNON HENRI DUFFAUT

  305 Rue RAOUL FOLLEREAU, 84902 Avignon

  ☎ 0432753333Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Transfer of the shared epitope through microchimerism in women with rheumatoid arthritis

  Arthritis and rheumatism · 2009

  📚 83 citations🎯 RCR 2.37Top 22% NIH

  Lire l'abstract Crossref ↓

  Abstract Objective Rheumatoid arthritis (RA) is an autoimmune disease that affects mostly women and is associated with HLA–DRB1 genes having in common a shared epitope sequence. In parallel, cells and/or DNA originating from pregnancy (microchimerism) persist for decades and could contribute to autoimmunity. The aim of this study was to examine whether microchimerism may be a source of the shared epitope among women with RA. Methods Women with RA and healthy women who lacked RA‐associated genes such as HLA–DRB1*01 (n = 33 and n = 46, respectively) and/or HLA–DRB1*04 (n = 48 and n = 64, respectively), were tested for DRB1*01 or DRB1*04 microchimerism by HLA‐specific quantitative polymerase chain reaction assays. As controls, alleles not associated with RA (DQB1*02 and DRB1*15/16) were also analyzed. Results Compared with healthy women, women (42% with RA had a higher frequency and higher levels of DRB1*04 microchimerism versus 8%; P = 0.00002) as well as DRB1*01 microchimerism (30% versus 4%; P = 0.0015). Moreover, no difference in microchimerism was observed for alleles not associated with RA. Conclusion Women with RA had microchimerism with RA‐associated HLA alleles, but not with non–RA‐associated HLA alleles, more often and at higher levels compared with healthy women. These observations are the first to indicate that microchimerism can contribute to the risk of an autoimmune disease by providing HLA susceptibility alleles.

• 2

  Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study

  Annals of the rheumatic diseases · 2016

  📚 35 citations🎯 RCR 1.36
• 3

  Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies

  Arthritis care & research · 2010

  📚 30 citations🩺 Clinique

  Lire l'abstract Crossref ↓

  AbstractObjectiveTo prospectively evaluate the predictive value of initial titers and subsequent variations of 3 rheumatoid arthritis–associated antibodies for outcomes at 30 months in patients with recent‐onset polyarthritis.MethodsIgM rheumatoid factor (RF), anti‐Sa (citrullinated vimentin) antibodies, anti–cyclic citrullinated peptide 2 (anti–CCP‐2) antibodies, modified Health Assessment Questionnaire score, Disease Activity Score in 28 joints, and Sharp/van der Heijde radiologic scores were determined at baseline and at 18 and 30 months in a cohort of consecutive HLA–DR‐typed treated patients with recent‐onset polyarthritis aiming at remission.ResultsAt inclusion, 113 (44.7%), 58 (22.9%), and 97 (38.3%) of 253 recent‐onset polyarthritis patients were positive for RF, anti‐Sa, and anti–CCP‐2, respectively; at 30 months, 85 (33.6%), 31 (12.4%), and 100 (39.5%) patients were similarly positive. A low titer of any particular antibody was associated with higher risks for seroreversion. Similar to their persistent absence, reversion of RF and anti–CCP‐2 was associated with low risks for severity. Patients who acquired RF or anti–CCP‐2 after inclusion trended toward a poor prognosis. Relative to RF and anti–CCP‐2 antibodies, only the presence of anti‐Sa at inclusion, especially at higher titers and even when it subsequently disappeared, significantly predicted more rapid radiographic damage and lower remission rates at 30 months.ConclusionIn treated recent‐onset polyarthritis, anti–CCP‐2 prevalence is stable or increases slightly, whereas anti‐Sa and RF frequently disappear. Subsequent reversion and conversion of RF and anti–CCP‐2 blur the prognostic significance of initial RF and anti–CCP‐2 positivity. Of the 3 antibodies, only anti‐Sa, even if it disappears afterward, independently predicts severe outcomes.

Publications scientifiques (7) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche